The Coapsys Device: Technique and Results

Chapter

Abstract

It is well known that functional mitral regurgitation (FMR) is a disease of the left ventricle in which the mitral valve (MV) is supposedly victimized while acting as an ‘innocent’ bystander. In ischemic FMR myocardial ischemia leads to regional left ventricular (LV) remodeling and mitral regurgitation (MR) that is a result of, rather than the cause of, such initial post infarction LV remodeling (Guy et al., J Am Coll Cardiol 43(3):377–383, 2004). Ventricular injury leads to mitral annular dilatation and posterior and inferior displacement of the postero-lateral papillary muscle (PLPM) resulting in tethering of the MV leaflets and diminution of leaflet coaptation (Timek et al., Circulation 108(Suppl 1):II122–II127, 2003) (Fig. 15.1) Yiu and colleagues found that the degree of FMR is dependent upon the interplay of several factors with the major determinant of an effective regurgitant orifice (ERO) being systolic mitral valvular tenting. Such tenting in turn is determined by papillary muscle (PM) displacement and the loss of systolic mitral annular contraction (Yiu et al., Circulation 102(12):1400–1406, 2000).

Unfortunately, in some subgroups, repair of FMR is associated with a 5 year survival rate of only 50 % and with a significant risk of recurrent MR (Miller, J Thorac Cardiovasc Surg 122(6):1059–1062, 2001). Mitral valve repair (MVr) has outcome benefits and is generally the technique preferred over MV replacement in select FMR patients less than 70 years old and with less than class IV heart failure (Gillinov et al., J Thorac Cardiovasc Surg 122(6):1125–1141, 2001; Grossi et al., J Thorac Cardiovasc Surg 122(6):1107–1124, 2001) Data from Dion and colleagues show that when FMR is treated early in its course, before the LV end diastolic diameter has increased beyond 6.5 cm, excellent outcomes can be achieved with subsequent positive ventricular remodeling (Braun et al., Ann Thorac Surg 85(2):430–436, 2008). Duran and colleagues, however, showed that ring annuloplasty does not protect against recurrent FMR in patients with severe displacement of the PLPM and that this papillary muscle displacement may predict annuloplasty failure (Matsunaga et al., J Heart Valve Dis 13(3):390–397, 2004). Although some studies have shown fewer congestive heart failure (CHF) episodes and hospitalizations with MVr (Shah et al., Ann Thorac Surg 80(4):1309–1314, 2005), no study has ever demonstrated an ultimate survival benefit from correcting FMR, and there is still controversy as to whether operating on end-stage FMR is even appropriate. Additionally, clinical controversy still exists as to the appropriate therapy for FMR. Currently the NIH sponsored Cardiothoracic Surgical Trials Network has finished enrolling patients with severe chronic FMR to randomization to either mitral repair or replacement in a study to address this issue (U.S. National Institutes of Health. Comparing the effectiveness of repairing versus replacing the heart’s mitral valve in people with severe chronic ischemic mitral regurgitation. [Internet]. Cited 15 Aug 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT00807040, 2013).

While the above debate centers on whether or how to correct the ‘leaking valve’ of FMR, the Coapsys device was designed to instead address the MV insufficiency by treating the pathologic processes causing FMR. The Coapsys device works by reshaping the LV, restoring the position of the postlero-lateral subvalvular apparatus, and reducing the antero-posterior dimension of the MV annulus.

Keywords

Ischemia Europe Cardiomyopathy Cardiol PTFE 

Abbreviations

CABG

Coronary artery bypass grafting

CHF

Congestive heart failure

CPB

Cardiopulmonary bypass

DCM

Dilated cardiomyopathy

ED

End diastole

EDPVR

End diastolic pressure volume relationships

ERO

Effective regurgitant orifice

ES

End systole

ESPVR

End systolic pressure volume relationships

FE

Finite element

FMR

Functional mitral regurgitation

LV

Left ventricle

MR

Mitral regurgitation

MV

Mitral valve

MVr

Mitral valve repair

PLPM

Postero-lateral papillary

PM

Papillary muscle

RA

Reduction annuloplasty

RESTOR-MV

The Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of Mitral Valve

TEE

Transesophageal echocardiography

References

  1. 1.
    Fukamachi K, McCarthy PM. Initial safety and feasibility clinical trial of the myosplint device. J Card Surg. 2005;20(6):S43–7.PubMedCrossRefGoogle Scholar
  2. 2.
    McCarthy PM, et al. Device-based change in left ventricular shape: a new concept for the treatment of dilated cardiomyopathy. J Thorac Cardiovasc Surg. 2001;122(3):482–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Guccione JM, et al. Myosplint decreases wall stress without depressing function in the failing heart: a finite element model study. Ann Thorac Surg. 2003;76(4):1171–80; discussion 1180.PubMedCrossRefGoogle Scholar
  4. 4.
    Grossi EA, et al. Intraoperative effects of the coapsys annuloplasty system in a randomized evaluation (RESTOR-MV) of functional ischemic mitral regurgitation. Ann Thorac Surg. 2005;80(5):1706–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Fukamachi K, et al. Optimal mitral annular and subvalvular shape change created by the Coapsys device to treat functional mitral regurgitation. ASAIO J. 2005;51(1):17–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Inoue M, et al. The Coapsys device to treat functional mitral regurgitation: in vivo long-term canine study. J Thorac Cardiovasc Surg. 2004;127(4):1068–76; discussion 1076–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Fukamachi K, et al. Changes in mitral annular and left ventricular dimensions and left ventricular pressure-volume relations after off-pump treatment of mitral regurgitation with the Coapsys device. Eur J Cardiothorac Surg. 2004;25(3):352–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Fukamachi K, et al. Off-pump mitral valve repair using the Coapsys device: a pilot study in a pacing-induced mitral regurgitation model. Ann Thorac Surg. 2004;77(2):688–92; discussion 692–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Mishra YK, et al. Coapsys mitral annuloplasty for chronic functional ischemic mitral regurgitation: 1-year results. Ann Thorac Surg. 2006;81(1):42–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Grossi EA, et al. Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J Am Coll Cardiol. 2010;56(24):1984–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Grossi EA, et al. Comparison of Coapsys annuloplasty and internal reduction mitral annuloplasty in the randomized treatment of functional ischemic mitral regurgitation: impact on the left ventricle. J Thorac Cardiovasc Surg. 2006;131(5):1095–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Carrick R, et al. Patient-specific finite element-based analysis of ventricular myofiber stress after Coapsys: importance of residual stress. Ann Thorac Surg. 2012;93(6):1964–71.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Department of Cardiothoracic SurgeryManhattan VA Medical CenterNew YorkUSA

Personalised recommendations